Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28414475 | 0.82 | CES2 (0.50) | TSHRKDM4ELMNAKMT2AMEN1 | |
| SCHEMBL489524 | 0.81 | TSHR (0.52) | CYP1A2TSHRCA12CA1CA2 | |
| SCHEMBL12457581 | 0.79 | CYP1A2 (0.46) | CYP1A2TSHRCYP2C9CYP2C19CA12 | |
| Bromide SCHEMBL28533203 | 0.79 | TSHR (0.50) | CYP1A2TSHRCA12CA1CA2 | |
| SCHEMBL9271700 | 0.78 | ALDH1A1 (0.45) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL12523424 | 0.78 | CYP1A2 (0.44) | CYP1A2TSHRCYP2C9CYP2C19CA12 | |
| SCHEMBL4921787 | 0.77 | CYP1A2 (0.41) | CYP1A2TSHRCYP2C9CYP2C19CA12 | |
| SCHEMBL31214229 | 0.76 | KMT2A (0.48) | CYP1A2TSHRCYP2C9CYP2C19CA12 | |
| SCHEMBL15260359 | 0.76 | HTT (0.44) | CYP1A2TSHRCYP2C9CYP2C19CA12 | |
| SCHEMBL12228825 | 0.76 | CYP1A2 (0.52) | CYP1A2TSHRKDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117412959-A | Substituted 1-aryl-1 '-heteroaryl compounds, substituted 1,1' -biaryl compounds, and methods of use thereof | 爱彼特生物制药公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117164499-A | Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-116836184-A | Preparation and application of Wee1 kinase inhibitor | 药雅科技(上海)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-112272553-B | Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-113767100-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-112272553-A | Substituted benzofurans, benzopyrrole, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-108026105-B | TGF-beta receptor antagonists | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-109928976-A | A kind of method of industrialized production EOC317 | 泰州亿腾景昂药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-1993130-B | Processes and intermediates used for preparing fused heterocyclic kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2010-06-23 | — | — | CN | disclosed |
| CN-101723948-A | C-6 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO | 2010-06-09 | — | — | CN | disclosed |
| CN-101365454-A | Substituted 4-amino-pyrrolotriazine derivatives for the treatment of hyperproliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-02-11 | — | — | CN | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| CN-1993130-A | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-07-04 | — | — | CN | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1726216-A | C-6 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2006-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | CYP1A2 578/4885TSHR 337/4885CYP2C9 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.